No Pharma Money We do not accept funding from organizations that profit from the development or distribution of prescription drugs.

David Mitchell embraced by President Biden at the White House

News & Reports

The latest from P4ADNow

The latest news, research, policy analysis, and updates from the fight to lower prescription drug prices.

Latest
Explainers
For Press

News Nov 13, 2026

The Week in Review in Prescription Drug Pricing: P4AD CEO to Testify at Senate Judiciary Hearing, ETHIC Momentum Grows, and more

Our CEO Merith Basey will testify at Tuesday’s Senate Judiciary Committee hearing, “Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs.” The hearing will focus on legislation to address the pharmaceutical industry’s abuse of the patent system — including through patent thickets, pay-for-delay deals, product hopping, and abuse of the citizen petition process.

Read The Full Story

Stay Up To Date

News and reports from P4ADNow

News Nov 22, 2024

This Week in Drug Pricing: PREVAIL Act Narrowly Clears Senate Judiciary Committee, Continued Push For Competition, President-Elect Trump 2025 Appointments, and ICYMI

After several delays, members of the Senate Judiciary Committee voted to pass S. 2220, the PREVAIL Act, by a razor-thin bipartisan margin of 11 yays to 10 nays.

Read Article News Nov 21, 2024

Patients For Affordable Drugs Now Expresses Disappointment Over Senate Judiciary Committee’s Advancement Of Patent Bill That Will Keep Drug Prices High For Patients

Patients For Affordable Drugs Now is disappointed to see the Senate Judiciary Committee advance a patent bill that would harm patients: S. 2220 the PREVAIL Act.

Read Article News Nov 15, 2024

This Week in Drug Pricing: Harmful Patent Bills Stall In Senate, Drug Industry Trade Association’s Waning Power and ICYMI

The Senate Judiciary Committee’s markup of two controversial patent bills, S.2220, the PREVAIL Act, and S.2140, the Patent Eligibility Restoration Act (PERA), was postponed yet again amidst ongoing…

Read Article News Nov 8, 2024

This Week in Drug Pricing: P4ADNow’s Commitment To Lower Prices Under New Administration, CAR-T: A Breakthrough Therapy Hindered By High Costs, and ICYMI

With the 2024 Presidential Election called for Former President Donald Trump, P4ADNow reiterated its commitment to addressing the high cost of prescription drugs through working with the incoming…

Read Article Press Releases Nov 6, 2024

Patients For Affordable Drugs Now Responds To Results Of The U.S. Presidential Elections

Following the U.S. Presidential Election being called for Former President Donald Trump, David Mitchell, Founder of Patients For Affordable Drugs Now, issued the following statement:

Read Article News Nov 1, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, Big Pharma Reaps Big Earnings, and ICYMI

Combined oral arguments brought by Bristol Myers Squibb (BMS), AstraZeneca, and Janssen Pharmaceuticals were heard by the Third Court of Appeals in Philadelphia in their efforts to halt the Medicare Negotiation Program.

Read Article News Oct 25, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, First Patient Leaves Hospital After SCD Therapy, Legislators Tout IRA Savings, and ICYMI

Marking another significant upset for Big Pharma and a critical victory for patients, Novartis faced a setback last week in its lawsuit to stop the implementation of the Medicare Negotiation Program.

Read Article News Oct 18, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, Bringing CAR-T Closer To Patients, Medicare “Smoothing” OOP Costs, and ICYMI

Novo Nordisk’s legal battle against the Medicare Negotiation Program has shifted gears, with the company now focusing on challenging elements of the program’s implementation rather than broad…

Read Article News Oct 11, 2024

This Week in Drug Pricing: Projected Savings From Out-of-Pocket Cap, Rising Prices Of Cancer Therapies, Patient Advocates At HHS Roundtable, and ICYMI

Asthma and chronic obstructive pulmonary disease (COPD) disproportionately affects Black, Latino, and Native American communities, as a result of key social determinants of health – such as air…

Read Article News Oct 4, 2024

This Week in Drug Pricing: CMS Guidance On 2nd Round Of Medicare Negotiation, Medicinas Vitales, No Lujos, Big Pharma CEOs Rake In Cash and ICYMI

The next round of the Medicare drug price negotiations has been designed to be more patient-centered, according to the Centers for Medicare & Medicaid Services (CMS).

Read Article

Explainers

Drug Pricing Explained

Videos breaking down the policies, practices, and decisions that shape what Americans pay for prescription drugs.

Patient advocate featured in The ETHIC Act Explained

The ETHIC Act Explained: What It Means for Patients

1:49 · Watch on YouTube

How Big Pharma Games the Patent System

3:50 · Watch on YouTube

Dr. Ramachandran discusses delays to Medicare drug price negotiation

Congress Delays Negotiation. Patients Pay the Price.

0:51 · Watch on YouTube

Help us spread the word

Subscribe To Our YouTube

For Press

Patients are available for interviews

Looking for a patient perspective or expert comment? We can connect you with patients, policy experts, and the latest research on prescription drug pricing.

[email protected]

Stay Connected

Stay informed about the latest campaigns, policy developments, and ways to help lower prescription drug prices.